However, 20–30% of the patients do not benefit from trastuzumab and even those who initially benefit experience disease recurrence in 10 years, which indicates a need for the identification of the factors and biomarkers that determine therapy response in HER2+ breast cancer [4]. This evidence concerns the gene ERBB2 and breast carcinoma.